Lipotoxicity has been implicated in the pathogenesis of obesity-related kidney damage and propagates chronic kidney injury like diabetic kidney disease; however, the underlying mechanisms have not yet been fully elucidated. To date, reduction of lipid acquisition and enhancement of lipid metabolism are the major, albeit non-specific, approaches to improve lipotoxic kidney damage. In the kidneys of high-fat diet (HFD)-fed mice and tubule cells cultured with palmitic acid (PA), we observed a dramatic upregulation of the long intergenic non-coding RNA-p21 (LincRNA-p21) through a p53-dependent mechanism. Kidney tubule cell-specific deletion of LincRNA-p21 attenuated oxidative stress, inflammation, apoptosis, and endoplasmic reticulum stress, leading to reduction of histological and functional kidney injury despite persistent obesity and hyperlipidemia. Mechanistically, HFD- or PA-initiated lipotoxicity suppressed the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR)/murine double minute 2 homolog (MDM2) signaling cascade to activate p53 and enhance the transcriptional activity of LincRNA-p21. Collectively, our findings suggest that the p53/LincRNA-p21 axis is the downstream effector in lipotoxic kidney injury and that targeting this axis particularly in the kidney tubule could be a novel therapeutic strategy.

INTRODUCTION

Obesity has been considered as a major risk factor for the development of chronic kidney disease, independent of its association with hypertension, diabetes, and dyslipidemia.1 Epidemiological studies have shown that intake of excess saturated fatty acid is a principal lifestyle-related cause of hyperlipidemia and related diseases, including non-alcoholic fatty liver disease and obesity-related kidney injury. During high-fat diet (HFD) feeding, the influx of free fatty acids results in the accumulation of triglycerides in other non-adipose tissues, termed lipotoxicity, and this induces oxidative stress, inflammation, apoptosis, endoplasmic reticulum (ER) stress, and insulin resistance, thus leading to pathological and functional aberrations in multiple organs, including the kidney.2

In addition to the well-known role of tumor protein 53 (p53) in tumor suppression, a plethora of evidence suggests the extensive involvement of p53 in the regulation of energy metabolism and numerous metabolic processes like aging, obesity, and diabetes3 by manipulation of cell metabolism, energy homeostasis, and cell fate. In HFD-treated animals, p53 was functionally elevated in various tissues accompanied with aggravated chronic inflammation, senescence, and systemic insulin resistance.3,4 Pharmacologic inhibition or genetic ablation of p53 in mice fed with HFD impeded excess fat accumulation, weight gain, hepatosteatosis, and insulin resistance.3,5 How p53 activates lipid metabolism in response to HFD treatment is not fully understood and it will be imperative to dissect the tissue- and cell-specific actions of p53 and its downstream signaling pathways in order to unravel a new paradigm of therapy for the chronic inflammatory state in obesity.

Long intergenic non-coding RNAs (lncRNAs), a class of non-coding RNAs over 200 nucleotides in length, have been a center of intense research in recent years and recognized as important regulators involved in diverse obesity-associated biological and cellular processes.6 lncRNA p21 (LincRNA-p21) is one of the most-studied lncRNAs due to its ability to fine-tune p53-dependent transcriptional responses.7 The name of LincRNA-p21 comes from its genetic location lying approximately 15 kb upstream from the Cyclin Dependent Kinase Inhibitor 1A (Cdkn1a, also called p21) gene on chromosome 17. Previous studies documented an integrative role of LincRNA-p21 in a variety of cellular functions, including modulation of cellular proliferation, inflammation, apoptosis, cell-cycle arrest, ER stress, gene expression, and protein stability.8,9 Especially noteworthy is that silencing LincRNA-p21 alleviated pathological changes in diabetic kidney.10 Nevertheless, little is known of whether LincRNA-p21 participates in obesity-related kidney injury.

The current study aims to dissect the role and mechanism of the p53/LincRNA-p21 signaling axis in the pathogenesis of lipotoxic injury arising from the chronic metabolic stress of excessive dietary fat consumption.
RESULTS

Generating a tubule-specific LincRNA-p21 knockout diet-induced obesity mouse model

Elevated expression of LincRNA-p21 was found in kidney tissue from obese db/db mice and HFD-fed obese mice (Figures 1A and 1B). To investigate the specific role of tubular LincRNA-p21 in diet-induced obesity (DIO) and associated metabolic disorders, tubule-specific LincRNA-p21 knockout (KO) mice and their control (CTL) littermates were generated (Figure S1) and fed normal diet (ND) or HFD for 8 weeks before sacrifice (Figure 1C). Gene KO was confirmed by quantitative real-time PCR (qRT-PCR) (Figure 1D). Tubule-specific LincRNA-p21 KO mice and their CTL littermates had normal appearance and no difference in the size or morphology of kidney. HFD-induced upregulation of LincRNA-p21 was reduced in KO mice as detected by qRT-PCR and fluorescence in situ hybridization (FISH) (Figures 1D and 1E).

Tubule-specific LincRNA-p21 deletion did not affect the development of obesity

HFD markedly increased BW in both KO and CTL mice from week 12 onward (Figure 2A), and no significant differences in body weight (BW) were observed for KO or CTL mice fed either ND or HFD (Figure 2B). Fasting blood glucose and serum lipids (Figures 2C–2E) were elevated by similar extents in both KO mice and CTL mice given HFD, indicating that tubular LincRNA-p21 does not affect the metabolic profile in HFD-induced obesity.

Tubule-specific LincRNA-p21 deletion protected kidney from HFD-Induced injury

HFD-induced increase in serum creatinine (sCr), blood urea nitrogen (BUN), and urinary albumin levels in HFD-fed CTL mice were improved after tubular LincRNA-p21 deletion (Figures 2F–2H). Periodic acid Schiff (PAS) staining (Figure 3A) demonstrates reduced kidney injury elicited by HFD in LincRNA-p21 KO mice, as shown by ameliorated mesangial expansion (assessed by glomerular tuft area) and tubular injury score (Figures 3B and 3C). HFD increased gene and protein expression of the tubular injury marker neutrophil gelatinase-associated lipocalin (NGAL), which was ameliorated by tubular LincRNA-p21 deletion (Figures 3D–3F). These findings suggest that LincRNA-p21 deficiency enhanced the kidney’s resilience to HFD-elicited injury.

Tubule-specific LincRNA-p21 deletion counteracted oxidative stress, inflammation, apoptosis, and ER stress

Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) is highly expressed in tubular epithelial cells of HFD-fed mice and was ameliorated by tubular LincRNA-p21 deletion (Figures 4A and 4B). Tubule-specific LincRNA-p21 deficiency significantly reduced

Figure 1. Characterization of LincRNA-p21 in kidney

(A) Increased expression of LincRNA-p21 in renal cortex from db/db mice versus their nondiabetic db/m mice. (B) Increased expression of LincRNA-p21 in renal cortex from diet-induced obese mice versus lean mice. (C) DIO protocol in tubule-specific LincRNA-p21 KO mice and their CTL littermates. (D) Renal cortical expression of LincRNA-p21 in KO or CTL mice fed with ND (KO-ND or CTL-ND) or HFD (KO-HFD or CTL-HFD) by qRT-PCR. (E) FISH showing the expression of nuclear LincRNA-p21 (orange) in kidney section from CTL-HFD mice and absence of nuclear LincRNA-p21 staining signal in KO-HFD mice. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) (>400). Data represent the mean ± SEM for five to seven mice per group. *p < 0.05.
the renal cortical expression (Figures 4C–4F) and systemic release (Figures 4G–4J) of pro-inflammatory cytokines including interleukin (IL)-1β, tumor necrosis factor alpha (TNF-α), monocyte chemoattractant protein (MCP-1), and IL-6. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling of fragmented DNA (TUNEL) assay showed an increased number of apoptotic cells in CTL-HFD mice, while LincRNA-p21 deletion decreased the apoptotic cell number in KO-HFD mice (Figures 5A and 5B). Furthermore, the transcript of pro-apoptotic marker C/EBP homologous protein (Chop), a marker of ER-stress-elicited apoptosis, was upregulated in CTL-HFD mice and reduced by LincRNA-p21 deletion (Figure 5C). Likewise, upregulation of pro-apoptotic mediator B-cell lymphoma 2-associated X protein (Bax) and downregulation of anti-apoptosis mediator B-cell lymphoma 2 (Bcl2) were observed in CTL-HFD mice and reduced by LincRNA-p21 deletion (Figure 5C). In vitro, PA and the p53 activators (RITA and Nutlin-3) induced elevation in both p53 activity (Figure 6G) and LINCRNA-p21 transcripts (Figure 6H) in HK-2 cells, while pretreating with the p53 inhibitor Pifithrin-α (PFT-α) partially reversed these elevations. Moreover, the elevated pro-apoptosis mediator BAX and suppressed anti-apoptosis mediator BCL2 in HK-2 cells exposed to PA and p53 activators (RITA and Nutlin-3) were partially reversed by PFT-α (Figures 6I and 6J). Taken together, these findings proposed that HFD suppressed PI3K/AKT/mTOR/MDM2 signaling to motivate the p53/LincRNA-p21 axis in obese kidney, while upregulated LincRNA-p21 possibly further inhibited PI3K/AKT/mTOR/MDM2 signaling cascade and aggravated lipotoxic kidney injury to generate a vicious cycle (Figure 7).

DISCUSSION

The present study sheds light on the role of LincRNA-p21, a key mediator of multiple biological processes, in lipotoxicity-induced kidney damage. We show for the first time that lipotoxicity-induced kidney lesions were suppressed by deletion of LincRNA-p21 in both cell culture and mouse models of DIO. Our findings provide convincing evidence that LincRNA-p21 deficiency in kidney tubule cells protects the kidney from multiple HFD-induced pathological responses,
including oxidative stress, inflammation and apoptosis, and ER stress. Mechanistically, our data demonstrate that lipotoxicity suppressed the PI3K/AKT/mTOR/MDM2 signaling cascade to enhance p53 transcriptional activity, which subsequently contributed to upregulation of LincRNA-p21 in kidney tubule cells. Taken together, these results highlight a connection between LincRNA-p21 and lipotoxicity-induced metabolic perturbation in tubule cells, corroborating a permissive role of LincRNA-p21 in metabolic disease.

Accumulating evidence proposes lncRNA to be a possible cellular hub for the coordination of cellular processes involved in multifarious kidney disease progression, and strategies targeting multiple individual lncRNAs have received attention as potential treatments for kidney diseases such as diabetic kidney disease (DKD). Podocyte-specific lncRNA taurine-upregulated 1 overexpressing DKD mouse models improved glomerular phenotype in terms of albuminuria and histological changes through protecting podocytes from apoptosis and ER stress and alleviating extracellular matrix (ECM) accumulation. More recent work suggests that two lncRNAs, Erbb4-IR and LRNA9884, promote DKD by enhancing kidney fibrosis and inflammation, respectively. Other lncRNAs, like metastasis-associated lung adenocarcinoma transcript 1, nuclear enriched abundant transcript 1, and zinc finger E-box-binding homeobox 1 antisense 1, 2 have been implicated in DKD or the maintenance of lipid metabolism homeostasis by regulating multiple pathophysiological processes like inflammation, fibrosis, and ER stress. Understanding of lncRNA in obesity-related kidney injury is still very limited. Emerging evidence unveils an integrative role of LincRNA-p21 in numerous cellular functions, including modulation of cellular proliferation, apoptosis, cell-cycle arrest, ER stress, gene expression, protein stability, and inflammation, thus eliciting extensive biological actions in multiple pathological conditions, like inhibiting liver fibrosis, facilitating angiogenesis in lung cancer, preventing atherosclerosis by affecting smooth muscle cell proliferation and apoptosis, promoting liver fibrosis, facilitating apoptosis of hepatocellular carcinoma cells via activating ER stress, and inhibiting invasion and metastasis of hepatocellular carcinoma. These evidence proposes LincRNA-p21 as a promising diagnostic and prognostic biomarker, as well as a therapeutic target, in human diseases. More importantly, it was found that LincRNA-p21 silencing alleviated pathological changes in diabetic kidney, and reduced ECM in mouse mesangial cells stimulated by high glucose, indicating the involvement of LincRNA-p21 in kidney disease. Mechanically, LincRNA-p21 acted as a molecular sponge for miR-18b that had inhibitory effects on connective tissue growth factor (CTGF)
expression via interaction with the 3′-UTR of CTGF, ultimately enhancing expression of collagen I, collagen II, and fibronectin in mesangial cells. Such observations prompted us to investigate the role of LincRNA-p21 in obesity-related kidney injury. Our findings for the first time highlighted a prominent role of LincRNA-p21 in obese kidneys and PA-stimulated tubular pathological processes.

Tubular damage is an early predictor of future functional decline in type 2 diabetes, and initial stages of kidney damage in obesity or pre-diabetes are characterized by the presence of serum lipid abnormalities and ectopic renal lipid accumulation. Therefore, the identification of early metabolic changes of lipotoxicity in tubule cells could be critical in understanding the pathogenesis of obesity-related kidney injury or DKD. To explore the functional role of LincRNA-p21, we generated a tubule-specific LincRNA-p21 KO mouse to unravel the potential of LincRNA-p21 to become an early tubular damage marker as well as a therapeutic target in lipotoxic kidney injury. LincRNA-p21 plays no regulatory role in lipid metabolism as its deletion did not affect serum lipid profile or BW in HFD-fed mice.

To elucidate the biological mechanisms through which LincRNA-p21 mediates obesity-related kidney lesion, we assessed cell oxidative stress, inflammation, apoptosis and ER stress in kidney tissue from HFD-induced obese mice and cultured tubular cells under PA treatment. Lipotoxicity-elicited oxidative stress, inflammation, apoptosis, and ER stress were blunted in the absence of LincRNA-p21, and alleviated the associated kidney dysfunction. Intriguingly, we found that tubule-specific LincRNA-p21 not only attenuated tubule injury but also contributed to reduced glomerular tuft area in HFD-induced obese mice. This finding reinforced the potential role of tubular injury...
in initiating loss of renal function with secondary sequelae that lead to glomerulosclerosis. The mostly accepted hypothesis of this phenomenon is that the overwhelming tubular glucose load due to increased plasma glucose levels during diabetes or pre-diabetes results in elevated proximal tubular sodium reabsorption through tubuloglomerular feedback, thus leading to a reduced afferent arteriolar vasoconstriction and subsequently glomerular hyperfiltration. Emerging evidence indicates that tubules may also contribute to glomerulopathy by secreting paracrine factors like nicotinamide mononucleotide and vascular endothelial growth factor (VEGF) that could diffuse back to the glomerulus to induce podocyte effacement, mesangial proliferation, and glomerular endothelial dysfunction in DKD. Others also reported an integrative functional role of LincRNA-p21 in mediating various pathological responses. In particular, absence of LincRNA-p21 resulted in a similar protective impact on a streptozotocin-induced DKD mouse model by reducing ECM in mesangial cells, alleviating kidney lesions, and hence improving renal function. In other words, LincRNA-p21 regulates both lipotoxic and glycemic kidney injury, albeit through different functional mechanisms in different resident kidney cells. Therefore, LincRNA-p21 may target multiple genes to regulate renal pathophysiology.

Our current data indicate that p53 is the upstream transcription factor that leads to LincRNA-p21 induction in obesity-related kidney lesions, proposing a novel mechanism by which p53 participates in the progression of metabolic disease. Importantly, pharmacological inhibition of p53 suppressed LincRNA-p21 expression and preserved its anti-apoptotic capability in PA-exposed renal tubule cells, consistent with previous findings. Here, we further showed that lipotoxicity directly suppressed the PI3K/AKT/mTOR/MDM2 signaling cascade to trigger p53 for its transcription of LincRNA-p21 through in vitro and in vivo studies, while upregulated LincRNA-p21 possibly further inhibits PI3K/AKT/mTOR/MDM2 signaling to enhance p53

![Figure 5. Tubule-specific LincRNA-p21 deletion reduces apoptosis and ER stress in HFD-fed mice](image-url)

Representative micrographs of TUNEL assay (A) and quantification of apoptotic cells (arrows) in kidney (B). mRNA levels of apoptotic markers Chop (C), Bax (D), Bcl2 (E), Bax/Bcl2 ratio (F), and ER stress marker Bip (G) in kidneys from HFD-fed mice. Data are expressed as mean ± SEM from each group (n ≥ 5), *p < 0.05. Transcripts of LncRNA-p21 (H), IL-6 (I), BIP (J), and CHOP (K) in HK-2 cells pretreated with LNA-lncRNA-p21 GapmeR and stimulated by PA (500 μM) or BSA (0.475%) for 24 h. Results are expressed as mean ± SEM. Experiments were performed in triplicate. *p < 0.05 versus Nil, #p < 0.05 versus LNA-CTL.
activity to result in a positive feedback loop of injury. Although we did not highlight the likely downstream molecular mechanism mediated by \textit{LincRNA-p21} during lipotoxic kidney injury, prior studies showed that the binding of \textit{LincRNA-p21} with MDM2 enhanced p53 transcriptional activity in vascular smooth muscle cells from atherosclerotic mice,\textsuperscript{30,39} and that the overexpression of \textit{LincRNA-p21} inhibited Wnt/β-catenin signaling in hepatic stellate cells,\textsuperscript{42} all supporting a crosstalk among \textit{LincRNA-p21}, PI3K/AKT/mTOR, and MDM2/p53 signaling cascades. Recent data recognized \textit{LincRNA-p21} as a molecular sponge to sequester microRNA-18b or microRNA-17-5p and promote the proliferation of mesangial cells exposed to high glucose or prevent activation of hepatic stellate cells,\textsuperscript{10,42} suggesting the classic mechanism that lincRNA as competitive endogenous RNAs or sponges of microRNAs to regulate gene expression could also be utilized by \textit{LincRNA-p21} to reduce lipotoxic kidney injury. We and others observed the potential of \textit{LincRNA-p21} to mediate p53 activity in a feedback manner,\textsuperscript{30,39} as well as the capacity of p53 in perturbing multiple biological processes under metabolic stress; however, we cannot exclude the possibility of \textit{LincRNA-p21} as an effective upstream regulator of p53 to regulate its function under lipotoxic kidney injury. This hypothesis merits future research for a better understanding of the molecular functions and molecular mechanisms of p53 family members.

Collectively, lipotoxicity suppressed the PI3K/AKT/mTOR/MDM2 signaling pathway to activate the downstream effectors p53/\textit{LincRNA-p21}, which trigger subsequent kidney injury. Tubule-specific ablation of \textit{LincRNA-p21} in kidney protected HFD-induced kidney injury structurally and functionally through ameliorating oxidative stress, inflammation, apoptosis, and ER stress. Our findings unraveled the potential of the tubular p53/\textit{LincRNA-p21} signaling axis in the regulation lipotoxicity-induced pathological cellular events, and opens a new avenue for developing treatment of lipotoxicity-elicited kidney injury.

**MATERIALS AND METHODS**

**Chemicals and reagents**

Dulbecco’s modified Eagle’s medium/Nutrient Mixture F-12 (DMEM/F12), GlutaMAX, 100 IU/mL penicillin, 100 μg/mL streptomycin, fetal bovine serum (FBS), and RNAiMAX reagent were purchased from Invitrogen (Carlsbad, CA). Custom-made locked nucleic acid (LNA) GapmeR antisense oligonucleotides targeting \textit{LincRNA-p21} (LNA-\textit{LincRNA-p21}) and corresponding negative CTL (LNA-CTL) were obtained from Qiagen (Germantown, MD), and Opti-MEM Reduced serum medium was obtained from Applied Biosystems (Carlsbad, CA). MDM2 inhibitor Nutlin-3, p53 inhibitor PFT-a, and p53 activator RITA (NSC 652287) were purchased from Selleckchem (Houston, TX). Fatty-acid-free BSA and PA were obtained from Sigma-Aldrich (St Louis, MO). PA was conjugated with BSA before being added into culture medium. In brief, 10% fatty-acid-free BSA solution dissolved in phosphate-buffered saline (PBS) was heated to 37°C before the addition of a 200 μM PA stock solution dissolved in absolute ethanol to gain a 10 μM working concentration, while a comparable concentration of 0.475% BSA was
thus the Ksp-CreERT2 ifen. The renal tubular epithelial cells upon activation by 4-hydroxytamoxifen were obtained from Professor Peter Igarashi (The UT Southwestern O’Brien Kidney Research Core Center, Dallas, TX) and the heterozygous LincRNA-p21^{fl/fl} mice were bought from the Jackson Laboratory (Main Street Bar Harbor, ME). For the generation of tubule-specific LincRNA-p21 KO mice, CreERT2 fusion protein expression is regulated exclusively under the kidney specific Ksp-Cadherin (Cadherin 16) gene promoter, thus the Ksp-CreERT2 fusion protein would specifically be found in the renal tubular epithelial cells upon activation by 4-hydroxytamoxifen. The LincRNA-p21^{fl/fl} mouse carries two loxp sites sandwiching the LincRNA-p21 sequence. By cross-breeding Ksp-CreERT2 and LincRNA-p21^{fl/fl} mice, we successfully generated the tubule-specific LincRNA-p21 KO, which carried both the Ksp-CreERT2 and LincRNA-p21^{fl/fl} alleles (Figure S1). These mice without Ksp-CreERT2 allele served as the CTL. At the age of week 6, 4-hydroxytamoxifen (1 mg/10 g BW) was administrated to all experimental mice (four groups, five to seven mice in each group) by daily intraperitoneal injection for five consecutive days to induce the Cre/loxP recombination in kidney tubules. qRT-PCR and FISH using Stellaris RNA FISH probe and reagents (LGC Biosearch Technologies, CA) were used to confirm the successful deletion of LincRNA-p21 (Figures 1D and 1E).

To establish DIO in KO and CTL mice, mice at week 8 were fed with HFD (60 kcal% fat, D12492, Research Diet Inc., NJ) for 8 weeks, whereas mice fed with ND (10 kcal% fat, D124350B, Research Diet Inc., NJ) served as CTL. BW was monitored biweekly. Blood was collected from tail vein following overnight fasting for renal function and biochemical analyses. Serum glucose levels were determined by Accu-Check Aviva glucometer (Roche Diabetes Care, Mannheim, Germany). Serum sCr, urinary creatinine, BUN, serum triglycerides, and cholesterol levels of mice were measured by enzymatic method (Stanbio Laboratory; St Boerne, TX). Urinary albumin was determined using an ELISA quantification kit (Bethyl Laboratories, TX). All mice were sacrificed at the end of experiments and kidneys were removed for histological analyses. Markers of oxidative stress, inflammation, apoptosis, and ER stress were evaluated by qRT-PCR, western blot analysis, and immunohistochemical (IHC) staining.

**RNA isolation and qRT-PCR**
Total RNA was isolated from HK-2 cells using NucleoSpin RNA II total RNA Isolation Kit (Macherey-Nagel, Duren, Germany). NucleoSpin TriPrep Kit (Macherey-Nagel) was used to extract total RNA from mouse renal cortex. Isolated RNA (2 μg) was utilized for synthesizing cDNA by High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qRT-PCR analyses were conducted in the StepOnePlus Real-time PCR Systems (Applied Biosystems) using SYBR Green Master Mix (Applied Biosystems) and specific primers (Table S1). Relative quantification of genes in each individual sample was normalized to β-actin expression and all experimental groups were compared with their respective CTL groups using StepOne software v2.3 (Applied Biosystems).

**Western blot analysis**
HK-2 cells were collected and washed with cold PBS after experiments and solubilized with lysis buffer (1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA) containing protease inhibitor cocktail (Thermo Scientific, CA). Total protein from mouse kidney cortex was isolated by NucleoSpin TriPrep Kit (Macherey-Nagel). Protein concentrations from the cultured cells or cortical lysates were detected by the BCA Protein Assay Reagent (Thermo Scientific). Equal amounts of proteins were separated on 4%–12% precast Bis-Tris gel (Bio-Rad, Hercules, CA) and then transferred from the gel to a 0.45-μm polyvinylidene difluoride membrane (Millipore, Bedford, MA) using standard electroblotting procedures. After blocking with 5% non-fat used as vehicle CTL for PA. All the other chemicals and reagents utilized in this study, unless otherwise specified, were obtained from Sigma-Aldrich.

**Generation of tubule-specific LincRNA-p21 KO mice**
All animal procedures were performed following the National Institutes of Health Guidelines for the Humane Treatment of Animals, with approval from the Committee on the Use of Live Animal in Teaching and Research of the University of Hong Kong. Diabetic db/db mice were obtained from The Jackson Laboratory (Main Street Bar Harbor, ME). The Ksp-CreERT2 mice were obtained from Professor Peter Igarashi (The UT Southwestern O’Brien Kidney Research Core Center, Dallas, TX) and the heterozygous LincRNA-p21^{fl/fl} mice were bought from the Jackson Laboratory (Main Street Bar Harbor, ME). For the Ksp-CreERT2 mice, CreERT2 fusion protein expression is regulated exclusively under the kidney specific Ksp-Cadherin (Cadherin 16) gene promoter, thus the Ksp-CreERT2 fusion protein would specifically be found in the renal tubular epithelial cells upon activation by 4-hydroxytamoxifen. The LincRNA-p21^{fl/fl} mouse carries two loxp sites sandwiching the LincRNA-p21 sequence. By cross-breeding Ksp-CreERT2 and LincRNA-p21^{fl/fl} mice, we successfully generated the tubule-specific LincRNA-p21 KO, which carried both the Ksp-CreERT2 and LincRNA-p21^{fl/fl} alleles (Figure S1). These mice without Ksp-CreERT2 allele served as the CTL. At the age of week 6, 4-hydroxytamoxifen (1 mg/10 g BW) was administrated to all experimental mice (four groups, five to seven mice in each group) by daily intraperitoneal injection for five consecutive days to induce the Cre/loxP recombination in kidney tubules. qRT-PCR and FISH using Stellaris RNA FISH probe and reagents (LGC Biosearch Technologies, CA) were used to confirm the successful deletion of LincRNA-p21 (Figures 1D and 1E).

To establish DIO in KO and CTL mice, mice at week 8 were fed with HFD (60 kcal% fat, D12492, Research Diet Inc., NJ) for 8 weeks, whereas mice fed with ND (10 kcal% fat, D124350B, Research Diet Inc., NJ) served as CTL. BW was monitored biweekly. Blood was collected from tail vein following overnight fasting for renal function and biochemical analyses. Serum glucose levels were determined by Accu-Check Aviva glucometer (Roche Diabetes Care, Mannheim, Germany). Serum sCr, urinary creatinine, BUN, serum triglycerides, and cholesterol levels of mice were measured by enzymatic method (Stanbio Laboratory; St Boerne, TX). Urinary albumin was determined using an ELISA quantification kit (Bethyl Laboratories, TX). All mice were sacrificed at the end of experiments and kidneys were removed for histological analyses. Markers of oxidative stress, inflammation, apoptosis, and ER stress were evaluated by qRT-PCR, western blot analysis, and immunohistochemical (IHC) staining.

**RNA isolation and qRT-PCR**
Total RNA was isolated from HK-2 cells using NucleoSpin RNA II total RNA Isolation Kit (Macherey-Nagel, Duren, Germany). NucleoSpin TriPrep Kit (Macherey-Nagel) was used to extract total RNA from mouse renal cortex. Isolated RNA (2 μg) was utilized for synthesizing cDNA by High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qRT-PCR analyses were conducted in the StepOnePlus Real-time PCR Systems (Applied Biosystems) using SYBR Green Master Mix (Applied Biosystems) and specific primers (Table S1). Relative quantification of genes in each individual sample was normalized to β-actin expression and all experimental groups were compared with their respective CTL groups using StepOne software v2.3 (Applied Biosystems).

**Western blot analysis**
HK-2 cells were collected and washed with cold PBS after experiments and solubilized with lysis buffer (1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA) containing protease inhibitor cocktail (Thermo Scientific, CA). Total protein from mouse kidney cortex was isolated by NucleoSpin TriPrep Kit (Macherey-Nagel). Protein concentrations from the cultured cells or cortical lysates were detected by the BCA Protein Assay Reagent (Thermo Scientific). Equal amounts of proteins were separated on 4%–12% precast Bis-Tris gel (Bio-Rad, Hercules, CA) and then transferred from the gel to a 0.45-μm polyvinylidene difluoride membrane (Millipore, Bedford, MA) using standard electroblotting procedures. After blocking with 5% non-fat
milk in Tris-buffered saline with Tween 20 (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.05% Tween 20), the blots were incubated with primary antibody overnight, washed with Tris-buffered saline with Tween 20, and then incubated with horseradish peroxidase-conjugated secondary antibody for 2 h and subsequently processed for incubation with enhanced chemiluminescence (ECL) prime chemiluminescence (GE healthcare, Buckinghamshire, UK) and visualized by ChemiDoc XR+ system (Bio-Rad). Intensity of the protein bands was measured via Image Lab software (Bio-Rad).

Morphometric analysis of the mice kidney sections
Kidney samples were fixed in 10% formalin, embedded in paraffin, and sectioned to 4-μm thickness. Morphologic analyses of the kidney sections were carried out after PAS staining (Sigma). Injured tubules in the renal cortex were assessed by the presence of necrosis, loss of brush borders, vacuolation, cast formation, and tubular dilatation. Tubular injury was scored from 0 to 5 according to the percentage of injured tubules (0, normal; 1, tubular lesion <10%; 2, 10%–20% lesion; 3, 20%–30% lesion; 4, 30%–50% lesion; 5, >50% lesion) from 10 randomly chosen, nonoverlapping fields at 400× magnification under a microscope. Glomerular tuft area was quantified by ImageJ software (National Institutes of Health, United States) from 20 randomly selected cortical glomeruli at 400× magnification and data were expressed as average μm2 per glomerulus. Only glomeruli containing a visible vascular or urinary pole were considered for area measurements.

Immunohistochemistry studies and apoptosis determination
In situ detection of apoptosis was performed using the ApopTag Peroxidase Kit (EMD Millipore, St Louis, MA) based on TUNEL staining, and data were expressed as number of apoptotic cells per high-power field. For IHC staining, paraffin-embedded kidney sections were deparaffinized and rehydrated, followed by microwave-based antigen retrieval in citrate buffer (10 mM), pH 6.0, or protease K solution (20 μg/mL) in Tris-EDTA buffer, pH 8.0. Sections were quenched by 3% hydrogen peroxide and blocked with 2% BSA. Primary antibodies against NGAL and NOX4 (Abcam, Cambridge, MA) were applied on the sections overnight, followed by incubation with peroxidase-conjugated secondary antibodies (Dako, Glostrup, Denmark). Sections were developed using 3,3′-diaminobenzidine substrate (Dako) and counterstained with hematoxylin. Ten images per section were captured in a blinded manner. Quantiﬁcation of staining was performed using ImageJ analysis software. Data were expressed as percentage of positively stained area.

Measurement of serum IL-β, TNF-α, IL-6, and MCP-1
Pro-inﬂammatory cytokines including IL-1β, IL-6, TNF-α, and MCP-1 in serum from all mice were measured in a single batch by Milliplex multiplex assays (EMD Millipore) according to the manufacturer’s instructions and using a Luminex 200 multiplex detection system (EMD Millipore).

Cell culture
The human proximal tubular cell line, human kidney 2 (HK-2) cells, was purchased from American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM/F12 fermented with 10% FBS, 1% penicillin/streptomycin at 37°C in 5% CO2. Cells were grown arrested in culture medium containing 0.5% FBS for 12 h before the initiation of all experiments.

LNA antisense oligonucleotides transfection in HK-2 cells
In vitro knockdown experiments were performed by using speciﬁc LNA GapmeR antisense oligonucleotides (ASOs). Three custom LNA GapmeR ASOs targeting LINCRNA-p21 (LNA-LINCRNA-p21: 5'-CTTGGCTGGCGGAAGG-3', 5'-CTTGGCTGGCGGAAGG-3' 5'-CTTGGCTGGCGGAAGG-3') and one LNA GapmeR ASO target-ting negative CTL (LNA-CTL: 5'-AAGATCTTTACGC-3') were used. One day before transfection, cells were plated in medium without antibiotics and FBS in a 12-well plate at a density that resulted in 60%–70% cell confluence. LNA-LINCRNA-p21 and LNA-CTL were diluted to the required concentration in Opti-MEM and mixed with Lipofectamine RNAiMAX, followed by incubation for 10 min at room temperature and then added to each well. Knockdown efﬁciency was determined 24 h after transfection by qRT-PCR, and cells with knockdown efficiency >70% were used for subsequent experiments.

Measurement of p53 activity
p53 activity in HK-2 cells with different treatments was measured using a p53 Transcription Factor Activity Assay Kit (BioVision, Mountain View, CA) according to the manufacturer’s speciﬁcations. This kit is a non-radioactive assay for the quantitative measurement of speciﬁc transcription factor DNA binding activity of active p53, and a biotin-labeled p53 response element DNA binds speciﬁcally to active p53 in nuclear extract and forms a complex that could be detected by the p53 speciﬁc monoclonal antibody. In brief, 5 μg of nuclear extract samples from HK-2 cells subjected to different culture conditions and CTLs were pipetted into wells precoated with a biotin-labeled p53 response element DNA that captures speciﬁcally active p53 to form a complex, which was then detected by adding anti-p53 monoclonal antibody that is conjugated to horseradish peroxidase streptavidin after removing unbound material by washing with washing buffer. Horseradish peroxidase catalyzed the conversion of a chromogenic substrate (tetramethylbenzidine) to a colored solution with color intensity proportional to the amount of protein present in the sample. Spectrophotometric data were expressed by measuring the absorbance at 450 nm using a microplate reader. Quantitative results were calculated from at least three independent biological experiments.

Statistical analysis
Statistical analysis was performed using Prism software version 7.0 (GraphPad, San Diego, CA). All data were expressed as mean ± SEM. Two-tailed Student’s t test or one-way ANOVA followed by a post hoc multiple comparison (Tukey) test was carried out where applicable. p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10. 1016/j.omtn.2021.10.029.

ACKNOWLEDGMENTS
The authors thank Prof. Peter Igarashi, the University of Texas Southwestern O’Brien Kidney Research Core Center (grant nos. NIHDP30DK079328 and R37DK042921), Institute of Genetics and Molecular and Cellular Biology, and Dr. Pierre Chambon for providing the Ksp-CreERT2 mouse strain. This study was supported by the Research Grants Council (C7018-16G, 17119818, 17108719); the Hong Kong Society of Nephrology Research Grant (2018); the International Postdoctoral Exchange Fellowship Program of China (Talent-introduction Program, YJ20200210); the National Natural Science Foundation of China (81870496, 82100747); the Croucher Senior Medical Research Fellowship awarded to S.C.W.T.; and by philanthropic donations from Dr. Rita T Liu SBS of L & T Charitable Foundation Ltd. and the Bingei Family of Indo Café, Mr. Winston Leung, Mr. K.K Chan of Hong Kong Concrete Co. Ltd., Ms. Lau Siu Suet, and HUI Hoy & CHOW Sin Lan Charity Fund and the Family of Mr. HUI Ming. W.H.Y. is supported by an Endowment Fund established at the University of Hong Kong for the Yu Professorship in Nephrology awarded to S.C.W.T. and research donations from Mr. and Mrs Tam Wing Fan. The funding bodies had no role in the design of the study, data collection, analysis and interpretation, or in writing the manuscript.

AUTHOR CONTRIBUTIONS
B.L., J.C.K.L., I.Y.Y.C., and H.Y.L. designed the study and carried out experiments. B.L. and J.C.K.L. analyzed the data, drafted the original manuscript, and created the figures. W.H.Y., S.W.Y.L., K.W.C., R.X., and Y.K.Z. helped with animal breeding and data collection. W.C., K.N.L., and S.C.W.T. reviewed and edited the writing, and covered the funding. All authors approved the final version of the manuscript. S.C.W.T. is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Stenmark, P., Zoccali, C., and Ix, J.Z. (2013). Obesity in CKD—what should nephrologists know? J. Am. Soc. Nephrol. 24, 1727–1736.
2. Li, B., Leung, J.C.K., Chan, L.Y.Y., Yu, W.H., and Tang, S.C.W. (2020). A global perspective on the crosstalk between saturated fatty acids and Toll-like receptor 4 in the etiology of inflammation and insulin resistance. Prog. Lipid Res. 77, 101020.
3. Kung, C.P., and Murphy, M.E. (2016). The role of the p53 tumor suppressor in metabolism and diabetes. J. Endocrinol. 231, R61–R75.
4. Liu, H., Kim, T.H., Franklin, D.A., and Zhang, Y. (2017). Protection against high-fat-diet-induced obesity in MDM2(C305F) mice due to reduced p53 activity and enhanced energy expenditure. Cell Rep. 18, 1005–1018.
5. Vergoni, B., Cornejo, P.J., Gillieron, J., Djejdiani, M., Ceppa, F., Jacqu, A., Bouget, G., Giné, C., Gonzalez, T., Maillet, J., et al. (2016). DNA damage and the activation of the p53 pathway mediate alterations in metabolic and secretory functions of adipocytes. Diabetes 65, 3062–3074.
6. Chen, C., Cui, Q., Zhang, X., Luo, X., Liu, Y., Zuo, J., and Peng, Y. (2018). Long noncoding RNAs regulation in adipogenesis and lipid metabolism: emerging insights in obesity. Cell Signal. 51, 47–58.
7. Huarte, M., Gutmann, M., Feldser, D., Garber, M., Koziol, M.J., Kenzelmann-Broz, D., Khalil, A.M., Zuk, O., Amit, I., Rabani, M., et al. (2010). A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142, 409–419.
8. Tang, S.S., Zheng, B.Y., and Xiong, X.D. (2015). LincRNA p21: implications in human diseases. Int. J. Mol. Sci. 16, 18732–18740.
9. Amirnejad, R., Rezaei, M., and Shirvani-Farsani, Z. (2020). An update on long intergenic noncoding RNA p21: a regulatory molecule with various significant functions in cancer. Cell Biosci. 10, 82.
10. Zhang, J., Cao, X., Wang, S., Aizimatis, M., Xiefu, R., and Liu, J. (2018). LincRNA-p21 sponges miR-18b to promote the progression of diabetic nephropathy. Am. J. Transl. Res. 10, 1481–1489.
11. Long, J., Balal, S.S., Ye, Z., Wang, Y., Ayanga, B.A., Galvan, D.L., Green, N.H., Chang, B.H., Overbeek, P.A., and Danesh, F.R. (2016). Long noncoding RNA Tug1regulates mitochondrial bioenergetics in diabetic nephropathy. J. Clin. Invest. 126, 4205–4218.
12. Duan, L.I., Ding, M., Hou, L.J., Cui, Y.T., Li, C.J., and Yu, D.M. (2017). Long noncoding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARgamma in diabetic nephropathy. Biochem. Biophys. Res. Commun. 484, 598–604.
13. Lei, X., Zhang, L., Li, Z., and Ren, J. (2018). Atragaloside IV/LncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats. Drug Des. Devel. Ther. 12, 2785–2793.
14. Shen, H., Ming, Y., Xu, C., Xu, Y., Zhao, S., and Zhang, Q. (2019). Deregulation of long noncoding RNA (TUG1) contributes to excessive podocytes apoptosis by activating endoplasmic reticulum stress in the development of diabetic nephropathy. J. Cell Physiol. https://doi.org/10.1002/jcp.28153.
15. Sun, S.F., Tang, P.M.K., Feng, M., Xiao, J., Huang, X.R., Li, P., Ma, R.C.W., and Lan, H.Y. (2018). Novel LncRNA erbb4-IR promotes diabetic kidney injury in db/db mice by targeting miR-29b. Diabetes 67, 731–744.
16. Zhang, Y.Y., Tang, P.M., Tang, P.C., Xiao, J., Huang, X.R., Yu, C., Ma, R.C.W., and Lan, H.Y. (2019). LRNA9884, a novel Smad3-dependent long noncoding RNA, promotes diabetic kidney injury in db/db mice via enhancing MCP-1-dependent renal inflammation. Diabetes 68, 1485–1498.
17. Hu, M., Wang, R., Li, X., Fan, M., Lin, J., Zhen, J., Chen, L., and Lv, Z. (2017). LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose-induced podocyte injury via its interplay with beta-catenin. J. Cell Mol. Med. 21, 2732–2747.
18. Li, Y., Ren, D., and Xu, G. (2019). Long noncoding RNA MALAT1 mediates high glucose-induced glomerular endothelial cell injury by epigenetically inhibiting klotho via methyltransferase G9a. JUBMB Life Sci. 71, 873–881.
19. Xiong, L., Gong, Y., Wu, L., Li, J., He, W., Zhu, X., and Xiao, H. (2020). LncRNA-MALAT1 is involved in lipotoxicity-induced cell dysfunction and the therapeutic effect of exendin-4 via Ptbp1. Endocrinology 161. https://doi.org/10.1210/endocto/bqa065.
20. Wang, X., Xu, Y., Zhu, Y.C., Wang, Y.K., Li, J., Li, Y.J., Ji., T., and Bai, S.J. (2019). LncRNA NEAT1 promotes extracellular matrix accumulation and epithelial-to-mesenchymal transition by targeting mir-27b-3p and ZEB1 in diabetic nephropathy. J. Cell Physiol. 234, 12926–12933.
21. Huang, S., Xu, Y., Ge, X., Xu, B., Peng, W., Jiang, X., Shen, L., and Xia, L. (2019). Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway. J. Cell Physiol. 234, 11200–11207.
22. Wang, J., Pan, J., Li, H., Long, J., Fang, F., Chen, J., Zhu, X., Xiang, X., and Zhang, D. (2018). LncRNA ZEB1-AS1 is suppressed by p53 for renal fibrosis in diabetic nephropathy. Mol. Ther. Nucleic Acids 12, 741–750.
23. Yang, J., Gan, X., Tan, B., Wang, J., and Chen, Y. (2019). Corticotropin-releasing factor suppresses glomerular progression by upregulation of long non-coding RNA p21. Life Sci. 216, 92–100.

24. Hall, J.R., Messenger, Z.J., Tam, H.W., Phillips, S.L., Recio, L., and Smart, R.C. (2015). Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes. Cell Death Dis. 6, e1700.

25. Yang, N., Fu, Y., Zhang, H., Sima, H., Zhu, N., and Yang, G. (2015). LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma. Oncotarget 6, 28151–28163.

26. Ye, Y., He, X., Lu, F., Hao, M., Zhu, Z., Yao, L., Luo, W., Sun, X., Wang, B., Qian, C., et al. (2018). A lincRNA-p21/miR-181 family feedback loop regulates microglial activation during systemic LPS- and MPTP-induced neuroinflammation. Cell Death Dis. 9, 803.

27. Yu, F.J., Guo, Y., Chen, B.C., Shi, L., Dong, P.H., Zhou, M.T., and Zheng, J.J. (2017). LincRNA-p21 inhibits the Wnt/beta-catenin pathway in activated hepatic stellate cells via sponging MicroRNA-17-5p. Cell Physiol. Biochem. 41, 1970–1980.

28. Yu, F., Lu, Z., Chen, B., Dong, P., and Zheng, J. (2016). Identification of a novel lincRNA-p21-miR-181b-PTEN signaling cascade in liver fibrosis. Mediators Inflamm. 2016, 9856538.

29. Castellano, J.J., Navarro, A., Vinolas, N., Marrades, R.M., Moises, J., Cordeiro, A., Saco, A., Munoz, C., Fuster, D., Molins, L., et al. (2016). LincRNA-p21 impacts prognosis in resected non-small cell lung cancer patients through angiogenesis regulation. J. Thorac. Oncol. 11, 2173–2182.

30. Wu, G.Z., Cai, J., Han, Y., Chen, J.H., Huang, Z.P., Chen, C.Y., Cai, Y., Huang, H.F., Yang, Y.J., Liu, Y.K., et al. (2014). LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation J 30, 1452–1465.

31. Tu, X.L., Zhang, Y.Y., Zheng, X.X., Deng, J., Li, H.N., Kang, Z.Q., Cao, Z.P., Huang, Z., Ding, Z., Dong, L., et al. (2017). TGF-beta-induced hepatocyte lincRNA-p21 contributes to liver fibrosis in mice. Scientific Rep. 7, 2957.

32. Tu, X., Zhang, Y., Zheng, X., Deng, J., Li, H., Kang, Z., Cao, Z., Huang, Z., Ding, Z., Dong, L., et al. (2017). TGF-beta-induced hepatocyte lincRNA-p21 contributes to liver fibrosis in mice. Scientific Rep. 7, 2957.

33. Ding, G., Peng, Z., Shang, J., Kang, Y., Ning, H., and Mao, C. (2017). LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through miR-9/E-cadherin cascade signaling pathway molecular mechanism. Onco Targets Ther. 10, 3241–3247.

34. Henegar, J.R., Bigler, S.A., Henegar, L.K., Tyagi, S.C., and Hall, J.E. (2001). Functional and structural changes in the kidney in the early stages of obesity. J. Am. Soc. Nephrol. 12, 1211–1217.

35. Li, B., Leung, J.C.K., Chan, L.Y.K., Yiu, W.H., Li, Y., Lok, S.W.Y., Liu, W.H., Chan, K.W., Tse, H.F., Lai, K.N., et al. (2019). Amelioration of endoplasmic reticulum stress by mesenchymal stem cells via hepatocyte growth factor/c-Met signaling in obesity-associated kidney injury. Stem Cells Transl. Med. 8, 898–910.

36. Thomson, S.C., Vallen, V., and Blantza, R.C. (2004). Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am. J. Physiol. Ren. Physiol. 286, F8–F15.

37. Nihalani, D., and Suzstak, K. (2013). Sirt1–Claudin-1 crosstalk regulates renal function. Nat. Med. 19, 1371–1372.

38. Dimke, H., Sparks, M.A., Thomson, B.R., Friesche, S., Coffman, T.M., and Quaggin, S.E. (2015). Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney. J. Am. Soc. Nephrol. 26, 1027–1038.

39. Zhou, L., Tian, Y., Guo, F., Yu, B., Li, I., Xu, H., and Su, Z. (2020). LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize p53 activation and alleviate breast cancer development. Cancer Immunol. Immunother. 69, 835–846.

40. Yuan, Y., Zhang, A., Qi, J., Wang, H., Liu, X., Zhao, M., Duan, S., Huang, Z., Zhang, C., Wu, L., et al. (2018). p53/Drp1-dependent mitochondrial fission mediates aldosterone-induced podocyte injury and mitochondrial dysfunction. Am. J. Physiol. Ren. Physiol. 314, F798–F808.

41. Li, Y., Liu, J., Li, W., Brown, A., Baddoo, M., Li, M., Carroll, T., Oxburgh, L., Feng, Y., and Saifudeen, Z. (2015). p53 Enables metabolic fitness and self-renewal of nephron progenitor cells. Development 142, 1228–1241.

42. Yu, F., Guo, Y., Chen, B., Shi, L., Dong, P., Zhou, M., and Zheng, J. (2017). LincRNA-p21 inhibits the Wnt/beta-catenin pathway in activated hepatic stellate cells via sponging MicroRNA-17-5p. Cell Physiol. Biochem.: Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 41, 1970–1980.